BioCentury | Mar 25, 2021
Management Tracks

Slaoui resigns from Vaxcyte, Centessa; plus moves at HHS, Fate, Inotrem, Immuneering, SwanBio and more

...development officer and scientific leader of its iPSC product platform, will assume all R&D responsibilities.Paris-based Inotrem S.A....
...partner of MRL Ventures Fund. BC Staff U.S. Department of Health and Human Services Fate Therapeutics Inc. Cue Health Inc. Inotrem S.A. Harpoon...
BioCentury | Dec 31, 2020
Product Development

Dec. 30 Quick Takes: Approval for Sinopharm vaccine follows report of 79% protection; plus Aprea, Axsome, Serum Institute, Pfizer-BioNTech, Moderna, Inotrem and Actinium

...proposal’s terms, the company would begin distributing the mRNA-based COVID-19 vaccine in May 2021.France designates Inotrem’s TREM-1...
...clinical trials and other research (CAPNET) designated a Phase IIa COVID-19 trial of nangibotide from Inotrem S.A....
BioCentury | Feb 13, 2020
Finance

Feb. 12 Financial Quick Takes: Trio of follow-ons; plus Teva, PentixaPharm, Inotrem

...a theranostic radiopharmaceutical pair targeting the CXCR4 receptor. Inotrem bumps up B round to €44Mt Inotrem S.A....
...to get lead program, TREM1 inhibitor nangibotide for septic shock, through Phase IIb testing (see "Inotrem...
...receptor 4 TREM1 - Triggering receptor expressed on myeloid cells 1 BioCentury Staff Adverum Biotechnologies Inc. Theravance Biopharma Inc. Inotrem S.A. PentixaPharm...
BioCentury | Sep 12, 2019
Financial News

Inotrem raises €39M series B for septic shock therapy, diagnostic

...A €39 million ($43 million) series B round raised by Inotrem will allow the French biotech...
...necessary to combat the infection (see “Inotrem: Sepsis Companion” ). CEO Jean-Jacques Garaud told BioCentury Inotrem...
...expects the funding to last until mid-2022. Morningside’s Jason Dinges joined Inotrem’s board. Mary Romeo, Assistant Editor Inotrem S.A. Sofinnova...
BioCentury | Feb 1, 2019
Company News

Inotrem gains rights to TREM1 biomarker for cardiovascular diseases

...a TREM1 inhibitor in Phase IIa testing for septic shock. Inotrem S.A., Paris, France Business: Cardiovascular Shannon Lehnbeuter Inotrem S.A. Triggering...
BioCentury | Oct 11, 2018
Clinical News

Inotrem reports 'favorable' markers for septic shock candidate

...Bangkok. The double-blind, European trial enrolled 49 septic shock patients to receive placebo or nangibotide. Inotrem...
...in the indication. Nangibotide, a TREM1 inhibitor, has PRIority MEdicines (PRIME) designation in the EU. Inotrem...
...and Roche (SIX:ROG; OTCQX:RHHBY) are partnered to develop a quantitative assay to detect soluble TREM1. Inotrem S.A....
BioCentury | Jan 18, 2018
Company News

Management tracks: Aslan, FIT Biotech

...Jan. 22. He was president of R&D at Forma Therapeutics Inc. (Watertown, Mass.). Inflammation company Inotrem S.A....
BioCentury | Nov 30, 2017
Company News

Inotrem, Roche to develop diagnostic for septic shock

...Inflammation play Inotrem S.A. (Nancy, France) and Roche (SIX:ROG; OTCQX:RHHBY) partnered to develop a diagnostic test to...
...and Roche's Elecsys platform. Inotrem S.A., Nancy, France Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Diagnostic, Inflammation Allison Johnson Inotrem S.A. Roche Triggering...
BioCentury | May 22, 2017
Financial News

Sofinnova Partners promotes Seghezzi

...Therapeutics (Waltham, Mass.), respiratory company Breath Therapeutics Holding B.V. (Munich, Germany) and sepsis treatment developer Inotrem S.A....
BioCentury | Nov 30, 2016
Distillery Therapeutics

Cardiovascular

...compared with normal TREM1 expression. Next steps could include testing TREM1 inhibitors in atherosclerosis models. Inotrem S.A....
Items per page:
1 - 10 of 19
BioCentury | Mar 25, 2021
Management Tracks

Slaoui resigns from Vaxcyte, Centessa; plus moves at HHS, Fate, Inotrem, Immuneering, SwanBio and more

...development officer and scientific leader of its iPSC product platform, will assume all R&D responsibilities.Paris-based Inotrem S.A....
...partner of MRL Ventures Fund. BC Staff U.S. Department of Health and Human Services Fate Therapeutics Inc. Cue Health Inc. Inotrem S.A. Harpoon...
BioCentury | Dec 31, 2020
Product Development

Dec. 30 Quick Takes: Approval for Sinopharm vaccine follows report of 79% protection; plus Aprea, Axsome, Serum Institute, Pfizer-BioNTech, Moderna, Inotrem and Actinium

...proposal’s terms, the company would begin distributing the mRNA-based COVID-19 vaccine in May 2021.France designates Inotrem’s TREM-1...
...clinical trials and other research (CAPNET) designated a Phase IIa COVID-19 trial of nangibotide from Inotrem S.A....
BioCentury | Feb 13, 2020
Finance

Feb. 12 Financial Quick Takes: Trio of follow-ons; plus Teva, PentixaPharm, Inotrem

...a theranostic radiopharmaceutical pair targeting the CXCR4 receptor. Inotrem bumps up B round to €44Mt Inotrem S.A....
...to get lead program, TREM1 inhibitor nangibotide for septic shock, through Phase IIb testing (see "Inotrem...
...receptor 4 TREM1 - Triggering receptor expressed on myeloid cells 1 BioCentury Staff Adverum Biotechnologies Inc. Theravance Biopharma Inc. Inotrem S.A. PentixaPharm...
BioCentury | Sep 12, 2019
Financial News

Inotrem raises €39M series B for septic shock therapy, diagnostic

...A €39 million ($43 million) series B round raised by Inotrem will allow the French biotech...
...necessary to combat the infection (see “Inotrem: Sepsis Companion” ). CEO Jean-Jacques Garaud told BioCentury Inotrem...
...expects the funding to last until mid-2022. Morningside’s Jason Dinges joined Inotrem’s board. Mary Romeo, Assistant Editor Inotrem S.A. Sofinnova...
BioCentury | Feb 1, 2019
Company News

Inotrem gains rights to TREM1 biomarker for cardiovascular diseases

...a TREM1 inhibitor in Phase IIa testing for septic shock. Inotrem S.A., Paris, France Business: Cardiovascular Shannon Lehnbeuter Inotrem S.A. Triggering...
BioCentury | Oct 11, 2018
Clinical News

Inotrem reports 'favorable' markers for septic shock candidate

...Bangkok. The double-blind, European trial enrolled 49 septic shock patients to receive placebo or nangibotide. Inotrem...
...in the indication. Nangibotide, a TREM1 inhibitor, has PRIority MEdicines (PRIME) designation in the EU. Inotrem...
...and Roche (SIX:ROG; OTCQX:RHHBY) are partnered to develop a quantitative assay to detect soluble TREM1. Inotrem S.A....
BioCentury | Jan 18, 2018
Company News

Management tracks: Aslan, FIT Biotech

...Jan. 22. He was president of R&D at Forma Therapeutics Inc. (Watertown, Mass.). Inflammation company Inotrem S.A....
BioCentury | Nov 30, 2017
Company News

Inotrem, Roche to develop diagnostic for septic shock

...Inflammation play Inotrem S.A. (Nancy, France) and Roche (SIX:ROG; OTCQX:RHHBY) partnered to develop a diagnostic test to...
...and Roche's Elecsys platform. Inotrem S.A., Nancy, France Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Diagnostic, Inflammation Allison Johnson Inotrem S.A. Roche Triggering...
BioCentury | May 22, 2017
Financial News

Sofinnova Partners promotes Seghezzi

...Therapeutics (Waltham, Mass.), respiratory company Breath Therapeutics Holding B.V. (Munich, Germany) and sepsis treatment developer Inotrem S.A....
BioCentury | Nov 30, 2016
Distillery Therapeutics

Cardiovascular

...compared with normal TREM1 expression. Next steps could include testing TREM1 inhibitors in atherosclerosis models. Inotrem S.A....
Items per page:
1 - 10 of 19